Dolutegravir: A next-generation integrase inhibitor for treatment of HIV infection

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages 265-271

  Osterholzer, Danielle A ^a   Goldman, Mitchell ^b  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

INSTI

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; CREATININE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; OMEPRAZOLE; PREDNISONE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR PLUS TIPRANAVIR; TELAPREVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ALLERGIC REACTION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERACTION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; VIRUS LOAD; ADVERSE EFFECTS; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; CREATININE; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLOMERULAR FILTRATION RATE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; TREATMENT OUTCOME;

EID: 84903997841     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu221     Document Type: Review

References (45)

1. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010; 53:124-30.
2. Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1 co-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011; 53:807-16.
3. Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: Final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013; 13:587-96.
4. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-48.
5. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
6. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008; 47:9345-54.
7. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764-74.
8. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54:254-8.
9. Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother 2013; 57:3536-46.
10. Weller S, Borland J, Chen S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol 2014; 70:29-35.
11. ViiV Healthcare. Prescribing information: Tivicay (dolutegravir) tablets for oral use. Available at: Www.viivhealthcarecom/media/58599/ us-tivicay.pdf. Accessed 29 October 2013.
12. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012; 56:1627-9.
13. Song IH, Borland J, Savina PM, et al. Pharmacokinetics of single dose dolutegravir in HIV seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev 2013; 2:342-8.
14. Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011; 55:3517-21.
15. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol 2011; 72:103-8.
16. Song I, Borland J, Chen S. Effect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects [abstract A1-1727]. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011.
17. Song I, Borland J, Lou Y, et al. Effects of enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572). In: 12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, FL, 2011:13-5.
18. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62:21-7.
19. Song I, Min SS, Borland J, et al. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 2011; 51:237-42.
20. Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 2013; 57:5472-7.
21. Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 2010; 55:365-7.
22. Song IH, Borland J, Chen S, Savina P, Peppercorn AF, Piscitelli S. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2013; 57:4394-7.
23. Johnson M, Borland J, Chen S, Savina P, Wynne B, Piscitelli S. The effect of boceprevir and telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects [abstract O-16]. In: 14th International Workshop on Clinical Pharmacology of HIV Therapy, Manchester, UK, 2013.
24. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-Administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011; 66:1567-72.
25. Song I. Dolutegravir has no effect on pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol [poster abstract 535]. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013.
26. Song I, Mark S, Chen S, et al. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug Alcohol Depend 2013; 133:781-4.
27. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemothe 2011; 55:813-21.
28. Da Silva D, Van Wesenbeeck L, Breilh D, et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010; 65:1262-9.
29. Hare S, Smith SJ, Metifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011; 80:565-72.
30. Vavro C, Dudas K, Hasan S, Huang J, Yeo J, Underwood M. Dolutegravir treatment of HIV subjects with raltegravir resistance: Integrase resistance evolution in cohort II of the VIKING study [abstract 5]. In: International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Melia Sitges, Sitges, Spain, 2012.
31. Smith F, Hammerstrom T, Soon G, et al. A meta-Analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Informat J 2011; 45:291-300.
32. Nichols G, Lazzarin A, Maggiolo F. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: Week 24 results of all 183 patients enrolled [abstract TULBPE19]. In: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Kuala Lumpur, Malaysia, June 30-July 3, 2013.
33. Nichols G, Mills A, Grossberg R, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: Week 24 phase 3 results from VIKING-3. J Int AIDS Soc 2012; 15 (suppl 4):18112.
34. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Antiretroviral drugs using plasma HIV RNA measurements- clinical considerations for accelerated and traditional approval. Center for Drug Evaluation and Research, 2002. Available at: Http://www.fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm070968.pdf. Accessed 10 January 2014.
35. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviralnaive adults with HIV-1: 96-week results from a randomized doseranging study. AIDS 2013; 27:1771-8.
36. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807-18.
37. Feinberg J, Clotet B, Khuong MA. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviral naive adults: 48 week results from FLAMINGO (ING114915) [abstract H-1464a]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013.
38. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, doubleblind, non-inferiority trial. Lancet Infect Dis. 2013; 13:927-35.
39. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381:735-43.
40. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382:700-8.
41. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013; 207:740-8.
42. van LJ, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/ GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: Planned interim 48 week results from SPRING-1, a doseranging, randomised, phase 2b trial. Lancet Infect Dis. 2012; 12:111-8.
43. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and paraaminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75:990-6.
44. Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV infected individuals. Department of Health and Human Services, 2013. Available at: Http://aidsinfo.nih.gov/ contentfiles/AdultARV-INSTIRecommendations.pdf. Accessed 14 January 2014.
45. ViiV Healthcare. Relative bioavailability study of two new dolutegravir/ abacavir/lamivudine fixed dose combination tablets. NCT01366547. NIH Clinical Trials Database, 2014. Available at: Www.clinicaltrials. gov. Accessed 9 January 2014.